Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.95 CAD 1.04% Market Closed
Market Cap: 126.1m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Arch Biopartners Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arch Biopartners Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Arch Biopartners Inc
XTSX:ARCH
Additional Paid In Capital
CA$7.5m
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
53%
Abcellera Biologics Inc
NASDAQ:ABCL
Additional Paid In Capital
$121.1m
CAGR 3-Years
174%
CAGR 5-Years
141%
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Additional Paid In Capital
CA$5.7m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
9%
Innovotech Inc
XTSX:IOT
Additional Paid In Capital
CA$1.6m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
11%
No Stocks Found

Arch Biopartners Inc
Glance View

Market Cap
125.3m CAD
Industry
Life Sciences Tools & Services

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

ARCH Intrinsic Value
0.29 CAD
Overvaluation 85%
Intrinsic Value
Price

See Also

What is Arch Biopartners Inc's Additional Paid In Capital?
Additional Paid In Capital
7.5m CAD

Based on the financial report for Jun 30, 2024, Arch Biopartners Inc's Additional Paid In Capital amounts to 7.5m CAD.

What is Arch Biopartners Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
53%

Over the last year, the Additional Paid In Capital growth was 13%. The average annual Additional Paid In Capital growth rates for Arch Biopartners Inc have been 17% over the past three years , 22% over the past five years , and 53% over the past ten years .

Back to Top